Soticlestat as Adjunctive Therapy in Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

Phase 3, open-label, single-arm trial of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome (LGS), sponsored by Takeda. Primary endpoints: Number of Participants With At Least One Treatment Emergent Adverse Event, Number of Participants in Each Category of the Columbia-Suicide Severity Rating Scale at Week 156 and 4 more. Started Mar 2022; status: terminated.